ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 0642 • ACR Convergence 2020

    COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies

    Marta González Fernández1, Orlando Pompei fernández2, Joaquín María Belzunegui Otano3, Paula García Escudero1, Claudia Stoye2, Juan Ramón De Dios2, Belén Álvarez Rodríguez2, Elena Garmendia Sánchez1, Susana Gil2, Ana Ruibal-Escribano4, Margarida Vasques Rocha2, Francisco García Llorente5, César Antonio Egües6, Edurne Guerrero7 and Jaime Calvo-Alén2, 1Hospital Universitario Cruces, Barakaldo, Spain, 2Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, 3Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, 4Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, 5Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, 6Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, 7Hospital Alto Deba, Arrasate, Pais Vasco, Spain

    Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
  • Abstract Number: 1625 • ACR Convergence 2020

    Pneumocystis Jiroveci Pneumonia in Immunocompromised Patients with Rheumatologic Disease in a Single, Tertiary Medical Center

    Zahra Rehman1, Megan Krause1, Jessica Newman2 and Pooja Bhadbhade1, 1The University of Kansas Medical Center, Kansas City, KS, 2The University of Kansas Medical Center, Kansas City

    Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is rare, but can be fatal among immunocompromised. There is no consensus on indications for PJP prophylaxis in rheumatologic patients.…
  • Abstract Number: 0455 • ACR Convergence 2020

    HLA-B27 and Host Immune Response: Lessons from Reactive Arthritis

    Sophie Wojcik1, Davina Morris2, Gillian Fitzgerald3, Steve Ramkissoon4, Nigil Haroon2 and Robert Inman5, 1UHN, Montreal, QC, Canada, 2University of Toronto, Toronto, ON, Canada, 3Toronto Western Hospital, Toronto, ON, Canada, 4UHN, Toronto, ON, Canada, 5University Health Network, Toronto, ON, Canada

    Background/Purpose: The natural history of reactive arthritis (ReA) remains poorly understood. Certain patients with ReA will go on to develop a chronic course while others…
  • Abstract Number: 0771 • ACR Convergence 2020

    Factors Associated to Clinical and Radiographic Disease Progression in Patients with Early RA and First-degree Relatives: A 1-year Follow-up

    Consuelo Romero-Sanchez1, Juan Manuel Bello-Gualtero2, Juliette De Avila3, Gloria Lafaurie4, Philipe Chalem Choueka5, Cesar Pacheco Tena6, Sebastian Giraldo-Q7, Jeimmy Andrea Chaparro-Sanabria8, Alejandro Ramos-Casallas3, Lorena Chila-M3 and Wilson Bautista-Molano9, 1Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, 2Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, 3Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, 4Universidad El Bosque, Basic Oral Research Unit – UIBO, School of Dentistry, Bogotá D.C., Colombia, 5Fundacion Instituto de Reumatología Fernando Chalem, Universidad El Rosario, Bogotá D.C., Colombia, 6Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, 7Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogota D.C., Colombia, 8Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, 9University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia

    Background/Purpose: In rheumatoid arthritis (RA), autoimmunity towards citrullinated peptides driven the hypothesis, in which periodontal disease (PD) is strongly related to the pathogenesis. Given the…
  • Abstract Number: 1685 • ACR Convergence 2020

    Impact of the COVID-19 Pandemic Among Children with Rheumatic Diseases from Around the Globe

    Jonathan Hausmann1, Kevin Kennedy2, Salman Surangiwala3, Maggie Larche4, Karen Durrant5, Rashmi Sinha6 and Emily Sirotich4, 1Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 2McMaster University, Hamilton, Canada, 3Queen’s School of Medicine, Kingston, Canada, 4McMaster University, Hamilton, ON, Canada, 5Autoinflammatory Alliance, San Francisco, CA, 6SJIA Foundation, Cincinnati

    Background/Purpose: Children with rheumatic diseases face unknown risks in the setting of the COVID-19 pandemic.  These children are often immunosuppressed due to their underlying disease…
  • Abstract Number: 008 • 2020 Pediatric Rheumatology Symposium

    Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases

    Mei-Sing Ong1, Deborah Rothman 2 and Marc Natter 3, 1Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, 2Massachusetts General Hospital, Springfield, 3Boston Children's Hospital, Boston

    Background/Purpose: B-cell depletion therapy has increasingly been used for the treatment of childhood-onset rheumatic diseases. Previous studies investigating whether rituximab results in increased infections have…
  • Abstract Number: 069 • 2020 Pediatric Rheumatology Symposium

    Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up

    Liora Harel 1, Gil Amarilyo 2 and mohammad hammad saied3, 1Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, 2Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel, 3Schneider Medical Center, Kaboul village 24963, Israel

    Background/Purpose: Rheumatic Fever (RF) occurs after a pharyngeal infection caused by group A-B-hemolytic streptococci.Its principal clinical significance is causing carditis at the acute phase of…
  • Abstract Number: 138 • 2020 Pediatric Rheumatology Symposium

    Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

    Simone Melega 1, Paul Brogan2, Gavin Cleary 3, Aimee Hersh 4, Ozgur Kasapcopur 5, Satyapal Rangaraj 6, Rae Yeung 7, Andrew Zeft 8, Jennifer Cooper 9, Pooneh Pordeli 10, Petra Kirchner 11 and Patricia Lehane 12, 1F. Hoffmann-La Roche, Ltd., Basel, Switzerland, 2UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 3Alder Hey Children's Hospital, Liverpool, United Kingdom, 4University of Utah Primary Children's Hospital, Salt Lake City, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Cerrahpasa, Turkey, 6Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, 7The Hospital for Sick Children, Toronto, Canada, 8The Cleveland Clinic - Center for Pediatric Rheumatology & Immunology, Cleveland, Ohio, 9University of Colorado, Children's Hospital Colorado, Denver, 10F. Hoffmann-La Roche, Ltd., Mississauga, Canada, 11F. Hoffmann-La Roche Ltd., Birsfelden, Switzerland, 12Roche Products Ltd., Welwyn Garden City, United Kingdom

    Background/Purpose: Low immunoglobulin (Ig) levels can occur after rituximab treatment, but the clinical significance is not completely understood. Not all patients (pts) who develop low…
  • Abstract Number: 1374 • 2019 ACR/ARP Annual Meeting

    Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US

    Robin Dore1, Jenya Antonova 2, Huan Huang 3, Lawrence Chang 2, Xin Wang 3 and Mark Genovese 4, 1Private practice, Tustin, CA, 2Gilead Sciences, Foster City, CA, 3IQVIA, Plymouth Meeting, PA, 4Stanford University, Stanford, CA

    Background/Purpose: Infections are common safety events monitored in RA patients.1 ACR guidelines limit the use of live vaccines in patients who are on biologic (b)DMARDs…
  • Abstract Number: 1515 • 2019 ACR/ARP Annual Meeting

    Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials

    Marina Magrey1, Victoria Navarro-Compán 2, Sandra Garces 3, Xenofon Baraliakos 4, David Sandoval 3, Jeffrey Lisse 3, Silvia Santisteban 3, David Adams 3, Fangyi Zhao 3 and Robert Inman 5, 1Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, 2University Hospital La Paz, IdiPaz, Madrid, Spain, 3Eli Lilly and Company, Indianapolis, IN, 4Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 5University of Toronto, University Health Network, Toronto, ON, Canada

    Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…
  • Abstract Number: 1805 • 2019 ACR/ARP Annual Meeting

    Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study

    Marianne Kerski1, Peter Boersma 2, Eric Miller 3, Ashley Brenner 4, Genevieve Melton 5 and Anna Shmagel 6, 1University of Minnesota Medical School, Minneapolis, MN, 2University of Minnesota School of Public Health, Minneapolis, 3University of Minnesota, Woodbury, MN, 4University of Minnesota Best Practices Integrated Informatics Core (BPIC), Minneapolis, MN, 5University of Minnesota Department of Surgery, Minneapolis, MN, 6University of Minnesota, Minneapolis, MN

    Background/Purpose: Perioperative management of anti-rheumatic drugs in rheumatoid arthritis (RA) patients undergoing surgery remains controversial. Previous studies produced conflicting results, and data on non-orthopedic surgeries…
  • Abstract Number: 2095 • 2019 ACR/ARP Annual Meeting

    A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients

    Kieran Murray1, Candice Low 1, Francis Young 1, Anna O'Rourke 1, Ian Callanan 2, Eoin Feeney 1 and Douglas Veale 3, 1Saint Vincent's University Hospital, Dublin, Ireland, 2Saint Vincent's University Hospital, Dublin, Dublin, Ireland, 3EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland

    Background/Purpose: The ACR and CDC recommend influenza (“flu”) and 23-valent pneumococcal polysaccharide (PPSV23) vaccination for inflammatory arthritis (IA) patients on immunosuppression. This study aimed to:…
  • Abstract Number: 2103 • 2019 ACR/ARP Annual Meeting

    Anti-TNF Therapy in Patients with HIV Infection

    Joanna Marco1 and Alison Bays 2, 1University of Washington, Seattle, WA, 2University of Washington Division of Rheumatology, Seattle, WA

    Background/Purpose: Patients with Human Immunodeficiency Virus (HIV) infection may benefit from the use of anti-Tumor Necrosis Factor (TNF) therapy in the setting of inflammatory disease,…
  • Abstract Number: 2107 • 2019 ACR/ARP Annual Meeting

    Comparison of the Management and Prognosis of Pneumonia in Patients with and Those Without Rheumatoid Arthritis Using the Japanese Diagnosis Procedure Combination Database

    Eishi Uechi1 and Kiyohide Fushimi 2, 1Tomishiro Central Hospital, Tomigusuku city, Okinawa, Japan, 2Tokyo Medical and Dental University Graduate School, Bunkyo-ku, Tokyo, Japan

    Background/Purpose: Pneumonia is a common cause of death not only in the general population but also in patients with rheumatoid arthritis (RA). In particular, patients…
  • Abstract Number: 2109 • 2019 ACR/ARP Annual Meeting

    Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study

    Jaime Coral-Enriquez 1, Mauricio Restrepo 2, Gloria Vasquez 3, Carlos H Muñoz-Vahos 4, Daniel Jaramillo 5, Adriana Vanegas-García 4, Ruth Eraso 6, Johanna Hernández 7, Fabian Jaimes 8 and Luis Gonzalez2, 1Grupo de Reumatología, Universidad de Antioquia, Medellin, Colombia, 2Grupo de Reumatología, Division of Rheumatology, Department of Internal Medicine, School of Medicine Universidad de Antioquia, Medellín, Colombia, 3University of Antioquia, Medellin, Antioquia, Colombia, 4Grupo de Reumatología, Universidad de Antioquia, Medellín, Antioquia, Colombia, 5Rheumatology unit, Hospital Universitario San Vicente Fundación, Medellin, Colombia, 6Grupo de Reumatología, Universidad de Antioquia; Pediatric rheumatology unit, Hospital Pablo Tobón Uribe, Medellin, Colombia, 7Division of Rheumatology, Pediatric Department, School of Medicine, Universidad de Antioquia, Medellín, Colombia, 8Department of Epidemiology, Hospital Universitario San Vicente Fundación, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia

    Background/Purpose: Tuberculosis (TB) infection is an important cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients, especially in developing countries. Previous studies have…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 36
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology